RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT made as of the _______ day of ___________________, 201__ (the “Grant Date”), between ImmunoGen, Inc. (the “Company”), a Massachusetts corporation, and ________________________ (the “Participant”).
PERFORMANCE BASED RESTRICTED STOCK AGREEMENTPerformance Based Restricted Stock Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
AGREEMENT made as of the _______ day of ___________________, 20__ (the “Grant Date”), between ImmunoGen, Inc. (the “Company”), a Massachusetts corporation, and ________________________ (the “Participant”).
EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENTExclusive License and Asset Purchase Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made effective as of May 23, 2017 (the “Effective Date”) by and between Debiopharm International, S.A., a Swiss limited company (“Debiopharm”) having a place of business at Forum “après-demain,” Chemin Messidor 5-7, Case Postale 5911, CH-1002 Lausanne, Switzerland, and ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”) having a place of business at 830 Winter Street, Waltham, MA 02451-1477, U.S.A. ImmunoGen and Debiopharm are sometimes each hereinafter referred to as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 4 TO THELicense Agreement • August 4th, 2017 • Immunogen Inc • Pharmaceutical preparations
This Amendment No. 4 to the Collaboration and License Agreement (this “Fourth Amendment”) is effective as of May 26, 2017 (the “Fourth Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation with a principal office at 830 Winter Street, Waltham, Massachusetts 02451 (“ImmunoGen”), and sanofi-aventis U. S. LLC, a Delaware limited liability company with a offices at 55 Corporate Drive, Bridgewater, NJ 08807 (“Sanofi”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Collaboration and License Agreement (the “Agreement”) dated as of July 30, 2003 (the “Agreement Effective Date”) by and between ImmunoGen and Aventis Pharmaceuticals, Inc. (“Aventis”), as amended August 31, 2006, October 11, 2007 and August 31, 2008.
